Search research articles
Contact Us
Filters
Showing results (121-130 of 868) with videos related to
Page
of 87
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2014
Best treatment strategies in high-risk multiple myeloma: navigating a gray area
Giada Bianchi, Paul G Richardson, Kenneth C Anderson
Immunotargets and Therapy
|
October 29, 2020
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Omar Nadeem, Yu-Tzu Tai, Kenneth C Anderson
Expert Opinion on Investigational Drugs
|
January 26, 2006
Current therapeutic uses of lenalidomide in multiple myeloma
Teru Hideshima, Paul G Richardson, Kenneth C Anderson
Molecular Cancer Therapeutics
|
November 11, 2011
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
Teru Hideshima, Paul G Richardson, Kenneth C Anderson
Cancer Control : Journal of the Moffitt Cancer Center
|
October 29, 2003
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers
Paul G Richardson, Teru Hideshima, Kenneth C Anderson
Reviews in Clinical and Experimental Hematology
|
February 7, 2004
Targeting proteasome inhibition in hematologic malignancies
Teru Hideshima, Paul G Richardson, Kenneth C Anderson
Hematology/Oncology Clinics of North America
|
September 13, 2014
Immunotherapy strategies in multiple myeloma
Jooeun Bae, Nikhil C Munshi, Kenneth C Anderson
Thescientificworldjournal
|
December 13, 2006
New frontiers in the treatment of multiple myeloma
Janice Jin Hwang, Irene M Ghobrial, Kenneth C Anderson
Cancer Research
|
July 25, 2006
Proteasome inhibitor drugs on the rise
Claudio A P Joazeiro, Kenneth C Anderson, Tony Hunter
Best Practice & Research. Clinical Haematology
|
July 20, 2005
Cytokines and signal transduction
Teru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Page
of 87
Search research articles
Search
Showing results (121-130 of 868) with videos related to
Sort By:
Page
of 87
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 4, 2014
Best treatment strategies in high-risk multiple myeloma: navigating a gray area
Giada Bianchi, Paul G Richardson, Kenneth C Anderson
Immunotargets and Therapy
|
October 29, 2020
Immunotherapeutic and Targeted Approaches in Multiple Myeloma
Omar Nadeem, Yu-Tzu Tai, Kenneth C Anderson
Expert Opinion on Investigational Drugs
|
January 26, 2006
Current therapeutic uses of lenalidomide in multiple myeloma
Teru Hideshima, Paul G Richardson, Kenneth C Anderson
Molecular Cancer Therapeutics
|
November 11, 2011
Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma
Teru Hideshima, Paul G Richardson, Kenneth C Anderson
Cancer Control : Journal of the Moffitt Cancer Center
|
October 29, 2003
Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers
Paul G Richardson, Teru Hideshima, Kenneth C Anderson
Reviews in Clinical and Experimental Hematology
|
February 7, 2004
Targeting proteasome inhibition in hematologic malignancies
Teru Hideshima, Paul G Richardson, Kenneth C Anderson
Hematology/Oncology Clinics of North America
|
September 13, 2014
Immunotherapy strategies in multiple myeloma
Jooeun Bae, Nikhil C Munshi, Kenneth C Anderson
Thescientificworldjournal
|
December 13, 2006
New frontiers in the treatment of multiple myeloma
Janice Jin Hwang, Irene M Ghobrial, Kenneth C Anderson
Cancer Research
|
July 25, 2006
Proteasome inhibitor drugs on the rise
Claudio A P Joazeiro, Kenneth C Anderson, Tony Hunter
Best Practice & Research. Clinical Haematology
|
July 20, 2005
Cytokines and signal transduction
Teru Hideshima, Klaus Podar, Dharminder Chauhan, et al.
Page
of 87